Compare RITM & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RITM | GRFS |
|---|---|---|
| Founded | 2011 | 1940 |
| Country | United States | Spain |
| Employees | 6045 | 25247 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.5B |
| IPO Year | N/A | N/A |
| Metric | RITM | GRFS |
|---|---|---|
| Price | $10.17 | $8.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $14.06 | $10.15 |
| AVG Volume (30 Days) | ★ 7.2M | 623.6K |
| Earning Date | 04-28-2026 | 07-28-2022 |
| Dividend Yield | ★ 9.83% | 1.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.69 |
| Revenue Next Year | $28.68 | $6.49 |
| P/E Ratio | ★ $10.21 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.43 | $6.90 |
| 52 Week High | $12.74 | $11.14 |
| Indicator | RITM | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 51.37 |
| Support Level | $9.41 | $8.27 |
| Resistance Level | $11.24 | $9.78 |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 89.60 | 53.61 |
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights), loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.